59P - Is there receptor tyrosine kinases expression on lymphocytes in patients with renal cell carcinoma? First-in-human study.

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Renal Cell Cancer
Basic Science
Genitourinary Cancers
Presenter Dmitry Khochenkov
Citation Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361
Authors D. Khochenkov1, M. Volkova2, A. Olshanskaia1, S. Aschuba1, Y. Khochenkova1, A. Anastasia Bondarenko3, I. Tsimafeyeu4
  • 1Laboratory Of Biomarkers And Mechanisms Of Tumor Angiogenesis, N.N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2Dept. Of Urology, N.N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 3General Medicine, Sechenov Medical University, Moscow/RU
  • 4Moscow Office, Kidney Cancer Research Bureau, Moscow/RU

Abstract

Background

To date little is known about receptor tyrosine kinases (RTK) expression on peripheral blood mononuclear cells (PBMC) and tumor infiltrating lymphocytes (TIL) in cancer patients. The aim of this study was to evaluate expression levels of major RTK: VEGFR1, VEGFR2, PDGFRα, PDGFRβ, FGFR2 in CD45+ population of PBMC and TIL isolated from patients with clear cell renal cell carcinoma (RCC).

Methods

Tumor and blood samples were obtained from 20 patients with RCC immediately after surgical resection of primary tumor. Tumors were harvested into sterile antibiotic-containing RPMI 1640 medium (Gibco). TIL isolation was performed under modified protocol [Baldan et al., 2015]. Isolated TIL and PBMC were prepared for flow cytometry. Cells were double stained with anti-CD45 FITC-conjugated mouse antibody, and with PE-conjugated mouse antibodies to VEGFR1, VEGFR2, PDGFRa, PDGFRb, FGFR2 (all Sony Biotech) and were analyzed on NovoCyte 2000R flow cytometer (ACEA Biosciences). Expression of RTK was evaluated with NovoExpress Software.

Results

Among PBMC 72.1±21.3% cells were CD45-positive. Isolated TIL contain 19.2±5.6% CD45-positive cells. PBMC and TIL express RTK. Expression levels of RTK are summarized in the table.Table:

59P

Expression of RTKPBMCTILP
VEGFR125.6±11.4%31.0±27.2%0,699
VEGFR223.8±11.1%53.2±29.3%0,096
PDGFRa48.0±18.9%45.4±16.7%0,833
PDGFRb63.3±28.7%66.7±26.1%0,843
FGFR241.2±27.8%23.6±12.3%0,168

Conclusions

To our knowledge, this is first study that showed significant RTK expression on peripheral and RCC-infiltrating lymphocytes in RCC patients. PBMC and TIL have similar RTK expression levels.

Clinical trial identification

Legal entity responsible for the study

Ethical committee, KCRB

Funding

Kidney Cancer Research Bureau

Disclosure

All authors have declared no conflicts of interest.